ImmunoPrecise

72 articles about ImmunoPrecise

• IPA’s Subsidiary Talem Therapeutics Licenses Antibodies for Three OmniChicken-Derived Programs

  10/12/2022

  IPA today announced that its subsidiary, Talem Therapeutics LLC (“Talem”), has entered into a multi-target license agreement with OmniAb, Inc., a subsidiary of Ligand Pharmaceuticals Incorporated.

• IPA Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2023

  9/14/2022

  IPA (ImmunoPrecise ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA), an advanced biotherapeutic research and technology company, today announced financial results for first quarter fiscal year 2023, which ended July 31, 2022.

• IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2023 on September 14, 2022

  9/8/2022

  IPA, an advanced biotherapeutic research and technology company, announced that it will host a conference call to discuss its quarterly results and recent business highlights for first quarter fiscal year 2023, on Wednesday, September 14, 2022, at 10:30 am Eastern Time.

• IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2022 on July 29, 2022

  7/26/2022

  IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA), an advanced biotherapeutic research and technology company, today announced that it will host a conference call to discuss its financial results and recent business highlights for fourth quarter and full fiscal year 2022, on Friday, July 29, 2022.

• Histopathology Data of Preclinical Repeated Dose Toxicity Study and ex vivo Human Tissue Cross-Reactivity (TCR) Analysis Support Safety of IPA’s PolyTope® TATX-03, a Synergistic Antibody Cocktail against SARS‑CoV‑2

  7/12/2022

  Histopathology Data of Preclinical Repeated Dose Toxicity Study and ex vivo Human Tissue Cross-Reactivity (TCR) Analysis Support Safety of IPA’s PolyTope® TATX-03, a Synergistic Antibody Cocktail against SARS ‑CoV‑2.

• ImmunoPrecise Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2022

  3/16/2022

  IMMUNOPRECISE ANTIBODIES LTD. today announced financial results for third quarter fiscal year 2022, which ended January 31, 2022.

• ImmunoPrecise Sets Third Quarter Fiscal 2022 Financial Results and Recent Business Highlights Conference Call for Wednesday, March 16th at 10:30 a.m. ET

  3/8/2022

  IMMUNOPRECISE ANTIBODIES LTD. today announced today announced that it will host a conference call to discuss its financial results and recent business highlights for third quarter fiscal year 2022, on Wednesday, March 16th, 2022, at 10:30 a.m. ET.

• ImmunoPrecise Relocates European Subsidiary to LEED Certified Campus to Continue to Advance its Antibody Research Operations and Environmental Sustainability

  1/18/2022

  IMMUNOPRECISE ANTIBODIES LTD. announced the relocation of its IPA Europe Oss laboratories to a new multi-tenant biotech Center of Excellence at the Pivot Park Campus in Oss, Netherlands.

• ImmunoPrecise Antibodies Announces Grant of Stock Options - Jan 11, 2022

  1/11/2022

  IMMUNOPRECISE ANTIBODIES LTD. announced that on January 7, 2022 its board of directors approved the grant of 170,000 stock options under its stock option plan to acquire up to an aggregate of 170,000 common shares in the capital of IPA.

• ImmunoPrecise Antibodies and ChemPartner Biologics Announce PolyTope® TATX-03 Antibody Cocktail Manufacturing Collaboration

  12/20/2021

  ImmunoPrecise Antibodies and ChemPartner Biologics Announce PolyTope ® TATX-03 Antibody Cocktail Manufacturing Collaboration.

• ImmunoPrecise Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2022

  12/7/2021

  IMMUNOPRECISE ANTIBODIES LTD. today announced that it will host a conference call to discuss its financial results and recent business highlights for second quarter fiscal year 2022 on December 13, 2021, after the close of market.

• ImmunoPrecise Update on its SARS-CoV-2 PolyTope™ Multi-Antibody Cocktail Development Program

  11/30/2021

  ImmunoPrecise Update on its SARS-CoV-2 PolyTope™ Multi-Antibody Cocktail Development Program.

• ImmunoPrecise to Present at the Benchmark Company’s Discovery One-on-One Virtual Video Investor Conference on Thursday December 2, 2021

  11/24/2021

  IMMUNOPRECISE ANTIBODIES LTD. is presenting at the Benchmark Company’s Discovery One-on-One Virtual Video Investor Conference. The conference is being held on December 2nd, 2021.

• IPA Announces Resignation of Director

  11/10/2021

  IMMUNOPRECISE ANTIBODIES LTD. announced that Paul Andreola, a member of the Board of Directors of IPA, has resigned, effective immediately, from the Company's Board of Directors for personal reasons unrelated to the Company.

• Talem Therapeutics Announces Multi-Target Antibody Discovery Research Collaboration With Pierre Fabre

  10/7/2021

  Talem Therapeutics Announces Multi-Target Antibody Discovery Research Collaboration With Pierre Fabre

• ImmunoPrecise’s Dutch Subsidiary Receives French Research Tax Credit (CIR) Accreditation

  9/8/2021

  ImmunoPrecise’s Dutch Subsidiary Receives French Research Tax Credit (CIR) Accreditation

• ImmunoPrecise Welcomes Vice President of Client Relations and Vice President of Marketing to its Leadership Team, Accelerating Its Growth and Expansion Plans

  8/4/2021

  IMMUNOPRECISE ANTIBODIES LTD. today announces the promotion of Dr. Barry Duplantis, Ph.D., to VP of Client Relations and welcomes Ms. Carla Dahl as VP of Marketing.

• ImmunoPrecise's PolyTope™ TATX-03 Antibody Cocktail Potently Neutralizes SARS-CoV-2 Delta Variant in in vitro Pseudovirus Assays

  7/22/2021

  ImmunoPrecise's PolyTope™ TATX-03 Antibody Cocktail Potently Neutralizes SARS-CoV-2 Delta Variant in in vitro Pseudovirus Assays

• ImmunoPrecise to Report Financial Results and Business Highlights for Fiscal Year 2021

  7/15/2021

  IMMUNOPRECISE ANTIBODIES LTD. today announced the Company will host a conference call to discuss its financial results and business highlights for the full fiscal year 2021.

• Eurofins Discovery and ImmunoPrecise Announce Collaboration to Expand their Antibody Discovery Platform

  6/22/2021

  IMMUNOPRECISE ANTIBODIES LTD and Eurofins Discovery announced a commercial collaboration.